| Old Articles: <Older 4811-4820 Newer> |
|---|
 |
The Motley Fool
April 30, 2008
Brian Lawler |
A Tale of 2 DNA Drugs More trouble for Genentech's No. 2 product, the systemic lupus treatment Rituxan.   |
The Motley Fool
April 30, 2008
Brian Orelli |
Medco's Far-From-Generic Quarter Pharmacy benefit manager Medco Health Solutions benefits from new generic drugs. |
The Motley Fool
April 30, 2008
Brian Lawler |
BioMarin's Bodacious Earnings BioMarin raises revenue guidance for all of its marketed drugs, thanks to strong sales so far in 2008. |
The Motley Fool
April 29, 2008
Brian Lawler |
Sciele's Blue-Moon Buyback The specialty pharmaceutical surprisingly renews its share repurchase plan. |
The Motley Fool
April 29, 2008
Brian Orelli |
Will These Drugs Get FDA Approval? Discovery Laboratories and Adolor are waiting FDA decisions on their drugs next month. |
The Motley Fool
April 29, 2008
Brian Lawler |
Medarex Takes Another Hit Its lead cancer-fighting drug suffers a regulatory delay. |
The Motley Fool
April 29, 2008
Brian Lawler |
So Pharmasset, So Good Early data hints at a promising hepatitis C treatment. |
The Motley Fool
April 29, 2008
Brian Orelli |
Merck's Recovery Flushed Down Merck's best hope at recovery fails approval by the FDA. |
The Motley Fool
April 28, 2008
Brian Lawler |
Flamel Inches Forward New sales data arrives for one lead drug, new promising data for another. |
The Motley Fool
April 28, 2008
Brian Lawler |
ImClone on the Upswing The pharmaceutical's latest results show continuing improvement. |
| <Older 4811-4820 Newer> Return to current articles. |
